OBJECTIVE: To review and summarize evidence from clinical, translational and epidemiologic studies which have examined the clinically relevant aspects of HPV type prevalence and cervical dysplasia in HIV-infected women. METHODS: Relevant studies were identified through a MEDLINE search. References of identified reports were also used to identify additional published articles for review. RESULTS: HIV-infected women in different geographic regions (such as Zambia, Brazil, Rochester NY) appear to be infected with less prevalent types of HR-HPV as compared to the general population who, across all continents, are more commonly infected with types 16 and 18. Secondly, integration of HPV DNA into the host genome is no longer thought to be a necessary cause of malignant transformation of cervical cells. However, rate of integration appears to differ by the type of HPV. In fact, the types of HPV which appear to be more common in cervical dysplasia of HIV-infected women are the same types which are more likely to require integration for malignant transformation. Finally, HPV types found in HIV-infected women are relatively common and likely to persist. The most common among these types belong to the alpha-9 and -7 species which are the most carcinogenic species. CONCLUSION: Given that current vaccines target HR-HPV-16/18, the findings from the above mentioned studies may have important implications for the design of HPV vaccines that target the types of HPV associated with disease risk in HIV-infected women. HPV typing and assessment of the physical state (whether it is integrated or episomal) appear to be two valuable parameters for the prognostic evaluation of dysplastic lesions of the uterine cervix. This, however, has not yet been assessed in HIV-infected women. Recent data about the immune response in HPV/HIV co-infection may lead to understanding potential mechanisms for less virulent HPV causing malignant transformation in HIV-infected women.
OBJECTIVE: To review and summarize evidence from clinical, translational and epidemiologic studies which have examined the clinically relevant aspects of HPV type prevalence and cervical dysplasia in HIV-infectedwomen. METHODS: Relevant studies were identified through a MEDLINE search. References of identified reports were also used to identify additional published articles for review. RESULTS:HIV-infectedwomen in different geographic regions (such as Zambia, Brazil, Rochester NY) appear to be infected with less prevalent types of HR-HPV as compared to the general population who, across all continents, are more commonly infected with types 16 and 18. Secondly, integration of HPV DNA into the host genome is no longer thought to be a necessary cause of malignant transformation of cervical cells. However, rate of integration appears to differ by the type of HPV. In fact, the types of HPV which appear to be more common in cervical dysplasia of HIV-infectedwomen are the same types which are more likely to require integration for malignant transformation. Finally, HPV types found in HIV-infectedwomen are relatively common and likely to persist. The most common among these types belong to the alpha-9 and -7 species which are the most carcinogenic species. CONCLUSION: Given that current vaccines target HR-HPV-16/18, the findings from the above mentioned studies may have important implications for the design of HPV vaccines that target the types of HPV associated with disease risk in HIV-infectedwomen. HPV typing and assessment of the physical state (whether it is integrated or episomal) appear to be two valuable parameters for the prognostic evaluation of dysplastic lesions of the uterine cervix. This, however, has not yet been assessed in HIV-infectedwomen. Recent data about the immune response in HPV/HIV co-infection may lead to understanding potential mechanisms for less virulent HPV causing malignant transformation in HIV-infectedwomen.
Authors: Mary C Cambou; Paula M Luz; Jordan E Lake; José Eduardo Levi; José Ricardo Coutinho; Angela de Andrade; Thais Heinke; Mônica Derrico; Valdilea G Veloso; Ruth K Friedman; Beatriz Grinsztejn Journal: AIDS Patient Care STDS Date: 2015-01 Impact factor: 5.078
Authors: Mary C Cambou; José Eduardo Levi; Jordan E Lake; Angela de Andrade; Emilia M Jalil; Fabio Russomano; Mônica Derrico; Valdilea G Veloso; Ruth K Friedman; Paula M Luz; Beatriz Grinsztejn Journal: Int J Infect Dis Date: 2015-10-28 Impact factor: 3.623
Authors: Craig D Woodworth; Laura P Diefendorf; David F Jette; Abdulmajid Mohammed; Michael A Moses; Sylvia A Searleman; Dan A Stevens; Katelynn M Wilton; Sumona Mondal Journal: Virology Date: 2011-10-05 Impact factor: 3.616
Authors: L Stewart Massad; Xianhong Xie; Robert D Burk; Gypsyamber D'Souza; Teresa M Darragh; Howard Minkoff; Christine Colie; Pamela Burian; Joel Palefsky; Jessica Atrio; Howard D Strickler Journal: Am J Obstet Gynecol Date: 2015-11-14 Impact factor: 8.661
Authors: Doreen Ramogola-Masire; Cindy M McGrath; Kurt T Barnhart; Harvey M Friedman; Nicola M Zetola Journal: Int J Gynecol Pathol Date: 2011-11 Impact factor: 2.762
Authors: Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153
Authors: Mario Jesus Trejo; Kennedy Lishimpi; Mulele Kalima; Catherine K Mwaba; Lewis Banda; Alick Chuba; Eslone Chama; Susan C Msadabwe; Melanie L Bell; Robin B Harris; Elizabeth Jacobs; Amr Soliman Journal: Int J Gynecol Cancer Date: 2020-03-21 Impact factor: 3.437